Based on the promising results, the company is advancing the tumor lysate, particle-loaded, dendritic cell vaccine into Phase III studies.
The study plans to recruit close to 300 patients with advanced non-small cell lung cancer, with half being treated based on liquid biopsy results.
The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.
The firm is using automated laboratory testing, artificial intelligence, and single-cell omics for a "precision" approach to cancer drug discovery.
A prospective study in 35 advanced melanoma patients found that response to combined Yervoy and Opdivo was correlated with the three markers.
The study has shown that patients on Zejula had longer progression-free survival than those on placebo regardless of their BRCA1/2 mutation or HRD status.
The differing effects of BRCA mutations by tumor lineage could have ramifications for treatments targeting the DNA repair process, the research team said.
In the 44-patient study, onvansertib will be studied in combination with Avastin and FOLFIRI in the second-line metastatic colorectal cancer setting.
The firm is focused on developing oncology drugs that target mutations in the RAS pathway.
The partners are working together to advance tests that will identify which cancer patients have Notch activating mutations and fusions.